Fatty Liver in Hormone Receptor-Positive Breast Cancer and Its Impact on Patient's Survival

Kartika Widayati Taroeno-Hariadi 1, Yasjudan Rastrama Putra 2, Lina Choridah 3, Irianiwati Widodo 4, Mardiah Suci Hardianti 1, Teguh Aryandono 5

1Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada - Dr. Sardjito Hospital, Yogyakarta, Indonesia
2Department of Internal Medicine, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada, Yogyakarta, Indonesia
3Department of Radiology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada - Dr. Sardjito Hospital Yogyakarta, Indonesia
4Department of Pathology, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada Yogyakarta - Dr. Sardjito Hospital, Yogyakarta, Indonesia
5Department of Oncology Surgery, Faculty of Medicine, Public Health and Nursing, Universitas Gadjah Mada Yogyakarta - Dr. Sardjito Hospital, Yogyakarta, Indonesia

ABSTRACT

Purpose: Long-term estrogen inhibition may cause fatty liver disease (non-alcoholic fatty liver disease; NAFLD) among other adverse conditions such as osteoporosis, climacteric symptoms, thromboembolism, dyslipidemia, and metabolic syndrome. The prevalence of NAFLD among breast cancer patients ranges from 2.3%–45.2%. This study aimed to determine the risk factors for newly developed NAFLD among breast cancer patients after hormonal treatment and whether it influences survival outcomes.

Methods: This retrospective study investigated hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative (HR+/HER2−), nonmetastatic breast cancer patients diagnosed between January 2010 and December 2018. All patients received adjuvant hormonal treatment for at least 6 months. Clinical data on metabolic profile indicators such as body mass index (BMI), waist circumference, serum cholesterol, triglycerides, low-density lipoprotein-cholesterol (LDL-C), high-density lipoprotein-cholesterol (HDLC), diabetes, and presence of metabolic syndrome (MetS) were collected. In total, 160 eligible patients with complete covariate data and survival follow-up were included.

Results: NAFLD was diagnosed in 35% of patients. There were significant associations of being overweight (BMI ≥ 25 kg/m²), waist circumference > 80 cm, triglycerides ≥ 150 mg/dL, HDL-C ≤ 50 mg/dL, LDL-C < 150 mg/dL, and presence of MetS with the development of NAFLD. However, unlike other factors, MetS and HDL-C were not independently associated with NAFLD. Patients with breast cancer who developed NAFLD had longer disease-free survival (DFS). The median DFS was not reached in the NAFLD group, whereas it was 59.3 (45.6–73.0) months in the non-NAFLD group. No worsening of overall survival was observed in patients with breast cancer and NAFLD.

Conclusion: The development of NAFLD during treatment in patients with HR+/HER2− breast cancer was associated with several independent risk factors: being overweight, waist circumference, triglycerides, and LDL-C. Interestingly, breast cancer patients with NAFLD during treatment had longer DFS than those without NAFLD.
INTRODUCTION

Non-alcoholic fatty liver disease (NAFLD) is a common clinicopathological result of chronic liver disease that is not caused by alcohol intake [1]. NAFLD affects 20%–30% of the general population and can be characterized by a wide spectrum of conditions such as noninflammatory intracellular fat deposition (marked by isolated steatosis) to nonalcoholic steatohepatitis (NASH; characterized by severe steatosis, inflammatory necrosis, and various degrees of fibrosis) [2]. NAFLD occurs due to the dysregulation of hepatic cholesterol homeostasis and accumulation of free cholesterol, free fatty acids, and triglycerides in the liver [3]. Furthermore, NAFLD is associated with insulin resistance, diabetes mellitus, metabolic syndrome, and abdominal obesity [2]. Increasing number of reports have suggested that NAFLD can implicated in the pathology of cardiovascular, pulmonary, and kidney diseases as well as cancers [2,4,5]. NAFLD is associated with a higher incidence rate of hepatic cellular carcinoma, colorectal cancer, and breast cancer [6,7].

Patients with breast cancer commonly develop NAFLD during the course of their disease. The incidence of NAFLD in breast cancer is approximately 2.3%–45.2% [8-10]. NAFLD seems to be associated with a patient’s metabolic profile and is influenced by breast cancer treatment, causing insulin resistance and cardiovascular complications [11]. Long-term estrogen inhibition with selective estrogen receptor modulators (SERMs) has been reported to cause NAFLD [12]. The incidence of fatty liver with tamoxifen (Tam) use is higher than that for aromatase inhibitor (AI) use [13]. However, the impact of NAFLD development in breast cancer patients after hormonal treatment has not yet been elucidated.

This study aimed to explore the prevalence, risk factors, and prognostic impact of NAFLD among nonmetastatic, hormone receptor (HR)-positive, human epidermal growth factor receptor (HER2)-negative or HR+/HER2− breast cancer patients who received adjuvant hormonal treatment.

METHODS

Ethics approval and patient selection

The Medical and Health Research Ethics Committee of the Faculty of Medicine, Universitas Gadjah Mada, approved this study (ref. No: KE/FK/1082/EC/2019). We retrospectively investigated HR+/HER2− nonmetastatic female breast cancer patients diagnosed between January 2010 and December 2018. Written informed consent was obtained from all the patients to access their medical data. Patients who received adjuvant hormonal treatment including Tam, AI, or Tam followed by AI (Tam + AI) for at least 6 months were included. These patients were only included if they also had metabolic and anthropometric data at their initial visit and had regular visits for clinical surveillance. Data on metabolic profile indicators such as body mass index (BMI), waist circumference, serum cholesterol, triglycerides, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), diabetes mellitus, and metabolic syndrome (MetS) were collected. MetS was defined according to the modified National Cholesterol Education Program Adult
Treatment Panel III (NCEP ATP III) for Asians [14,15]. Metabolic data were collected only for the first visit or before hormonal treatment.

The presence of any three of the following five metabolic criteria was defined as MetS: 1) high waist circumference (male > 90 cm, female > 80 cm); 2) elevated triglycerides or use of medication for hypertriglyceridemia (triglyceride ≥ 150 mg/dL); 3) low HDL-C (male ≤ 40 mg/dL, female ≤ 50 mg/dL); 4) hyperglycemia (fasting glucose level ≥ 100 mg/dL); and 5) hypertension or use of medication for hypertension (systolic ≥ 130 mmHg or diastolic ≥ 85 mmHg).

Fatty liver was qualitatively diagnosed using conventional ultrasonography (USG), based on the increased echogenicity of the liver parenchyma as compared to the right kidney cortex, as well as visibility and sharpness of the diaphragm and liver veins [16]. All patients underwent baseline breast imaging, abdominal USG, chest radiography, and bone survey. NAFLD diagnosed during adjuvant hormonal treatment was analyzed based on patient characteristics, metabolic risk factors, and type of hormonal treatment. Patients with NAFLD at baseline, previously documented liver disease, incomplete covariate data, incomplete clinical, histological, and imaging data for tumor assessment, or those who declined cancer treatment before completing 85% of the planned dosage, had double malignancy, or had severe comorbidities were excluded from the analysis.

**Recurrence and survival data**

Recurrence was assessed during surveillance at 6 month-intervals by clinical examination and breast and abdominal USG. Chest X-ray, mammography, and bone surveys were performed yearly according to the clinical protocol in our hospital. Recurrence event was defined as the reappearance of cancer or metastases detected by clinical, imaging, or cytologic procedures. Death status was collected from hospital death certificates or from the patient’s family information.

Disease-free survival (DFS) was calculated from the date of pathology result of the primary tumor until the date of the earliest documented recurrence or metastasis, death from any cause, or until the end of follow-up. Overall survival (OS) was calculated from the date of pathology result of the primary tumor until the date of death or until the end of follow-up. The last date of follow-up for survival (end of study) was December 31, 2019. DFS and OS were analyzed based on newly developed NAFLD.

**Statistical analysis**

Independent t-test and \( \chi^2 \) test were used to compare continuous and categorical data, respectively. Multivariate logistic regression analysis was used to identify potential independent risk factors that contributed to the development of NAFLD. Kaplan-Meier survival curve and Cox regression hazard model were applied to show the effect of NAFLD on prognosis of HR+/HER2− breast cancer. All statistical analyses were conducted using SPSS version 23 (IBM Corp., Armonk, USA).

**RESULTS**

A total of 1,612 HR+/HER2− breast cancer cases were diagnosed between January 2010 and December 2018. However, only 160 (9.93%) patients were eligible for the analysis (Figure 1). As compared to the larger (1,612 cases) HR+/HER− breast cancer cohort, the 160 eligible
HR+/HER2− cases had a less aggressive phenotype. Nodes 0 and 1 were more common in our samples than in the larger cohort \((p < 0.001)\), as were early-stage patients. Ductal invasive types were more common in our sample compared to the larger cohort, as shown in Supplementary Table 1.

The median age at diagnosis was 49 years (range, 32–74 years). The median follow-up time was 46.3 months (range, 7.8–116.7 months of observation).

Tam was used in 77 (48.1%) patients, whereas Tam + AI was used in 29 (18.1%) patients, and AI was used in 54 (33.8%) patients. MetS was detected in 87 (54.4%) patients, whereas obesity was detected in 15 (9.4%). Seventy-four patients (46.3%) had a BMI \(\geq 25\) kg/m\(^2\). NAFLD was diagnosed in 56 patients (35.0%). The mean onset of NAFLD after hormonal therapy was 23.5 ± 17.8 months. The baseline characteristics of HR+/HER2− breast cancer patients who developed NAFLD compared to those who did not develop NAFLD are described in Table 1. Being overweight, presence of MetS or its component, and having low LDL were more common in patients who developed NAFLD during treatment (Table 1).

**Risk factors for NAFLD**

There were significant associations between being overweight (odds ratio [OR], 3.526; 95% confidence interval [CI], 1.780–6.985; \(p < 0.001\)), waist circumference \(\geq 80\) cm (OR, 6.111; 95% CI, 2.407–15.518; \(p = 0.001\)), triglyceride level \(\geq 150\) mg/dL (OR, 6.111; 95% CI, 1.780–6.985; \(p = 0.001\)), HDL-C \(\leq 50\) mg/dL (OR, 6.111; 95% CI, 2.407–15.518; \(p = 0.001\)), and MetS (OR, 3.446; 95% CI, 1.700–6.987; \(p = 0.001\)). Tam use increased the risk of NAFLD but this was not statistically significant (OR, 1.439; 95% CI, 0.71–2.190; \(p = 0.310\)).
### Table 1. Baseline characteristics based on groups developed NAFLD and no-NAFLD

| Characteristics | NAFLD (n = 56) | No NAFLD (n = 104) | p* |
|-----------------|---------------|-------------------|----|
| **Age (yr)**    | 49.70 ± 7.786 | 50.92 ± 8.842     | 0.385 |
| Tumor size      |               |                   |    |
| T1              | 9 (16.1)      | 16 (15.4)         | 0.807 |
| T2              | 20 (35.7)     | 42 (40.4)         |    |
| T3              | 20 (35.7)     | 30 (28.8)         |    |
| T4              | 7 (12.5)      | 16 (15.4)         |    |
| Nodal           |               |                   |    |
| N0              | 39 (69.6)     | 61 (58.7)         | 0.301 |
| N1              | 10 (17.9)     | 30 (28.8)         |    |
| N2              | 7 (12.5)      | 11 (10.6)         |    |
| N3              | 0 (0)         | 2 (1.9)           |    |
| Grade           |               |                   |    |
| Grade 1–2       | 43 (48.9)     | 18 (41.9)         | 0.451 |
| Grade 3         | 45 (51.1)     | 25 (58.1)         |    |
| Ki-67           |               |                   |    |
| < 20%           | 18 (64.3)     | 14 (87.5)         | 0.096 |
| ≥ 20%           | 10 (35.7)     | 2 (12.5)          |    |
| BMI (kg/m²)     |               |                   |    |
| ≥ 25            | 37 (66.1)     | 37 (35.6)         | < 0.001 |
| < 25            | 19 (33.9)     | 67 (64.4)         |    |
| Menopause       |               |                   |    |
| Pre-menopause   | 17 (30.4)     | 38 (36.5)         | 0.430 |
| No menopause    | 39 (69.6)     | 66 (63.5)         |    |
| Waist (cm)      |               |                   |    |
| ≥ 80            | 50 (89.3)     | 60 (57.7)         | < 0.001 |
| < 80            | 6 (10.7)      | 44 (42.3)         |    |
| Cholesterol (mg/dL) |       |                   |    |
| ≥ 200           | 29 (51.8)     | 47 (45.2)         | 0.462 |
| < 200           | 27 (48.2)     | 56 (54.8)         |    |
| Triglyceride (mg/dL) |      |                   |    |
| ≥ 150           | 27 (48.2)     | 26 (25.0)         | 0.003 |
| < 150           | 29 (51.8)     | 78 (75.0)         |    |
| HDL-C (mg/dL)   |               |                   |    |
| ≤ 50            | 31 (55.4)     | 37 (35.6)         | 0.016 |
| > 50            | 25 (44.6)     | 67 (64.4)         |    |
| LDL-C (mg/dL)   |               |                   |    |
| ≥ 150           | 32 (57.14)    | 76 (73.1)         | 0.040 |
| < 150           | 24 (42.86)    | 28 (26.9)         |    |
| Fasting glucose (mg/dL) |   |                   |    |
| ≥ 100           | 37 (66.1)     | 68 (65.4)         | 0.93 |
| < 100           | 19 (33.9)     | 36 (34.6)         |    |
| Hypertension    |               |                   |    |
| Yes             | 28 (50.0)     | 57 (54.8)         | 0.561 |
| No              | 28 (50.0)     | 47 (45.2)         |    |
| MetS            |               |                   |    |
| Yes             | 41 (73.2)     | 46 (44.2)         | < 0.001 |
| No              | 15 (26.8)     | 58 (55.8)         |    |
| Chemotherapy    |               |                   |    |
| Yes             | 51 (91.1)     | 102 (98.1)        | 0.052 |
| No              | 5 (8.9)       | 2 (1.9)           |    |
| Adjuvant hormone|               |                   |    |
| Tam             | 30 (53.6)     | 47 (45.2)         | 0.544 |
| Tam + Al        | 10 (17.8)     | 19 (18.3)         |    |
| Al              | 16 (28.6)     | 38 (36.5)         |    |
| Mean onset of NAFLD after adjuvant hormone | 23.55 ± 17.800 |

Values are expressed as number (%) or mean ± standard deviation.

NAFLD = non-alcoholic fatty liver disease; Ki-67 = proliferation index; BMI = body mass index; HDL-C = high density lipoprotein cholesterol; LDL-C = low density lipoprotein cholesterol; MetS = metabolic syndromes; Tam = tamoxifen; AI = aromatase inhibitor; Tam + Al = tamoxifen for 2 years followed by AI.

*p* Calculated with Pearson χ² test; *p* < 0.05 was considered as statistically significant (bold-faced).
Multivariate logistic regression determined the independent risk factors for NAFLD: being overweight (OR, 2.270; 95% CI, 1.012–5.093; \( p = 0.047 \)), waist circumference > 80 cm (OR, 4.138; 95% CI, 1.428–11.992; \( p = 0.009 \)), LDL-C < 100 mg/dL (OR, 3.233; 95% CI, 1.435–7.284; \( p = 0.005 \)), and triglyceride level ≥ 150 mg/dL (OR, 2.265; 95% CI, 1.054–4.865; \( p = 0.036 \)) (Table 2).

Only seven patients with breast cancer received hormone treatment without chemotherapy. The risk of NAFLD for patients who received only hormone treatment without adjuvant chemotherapy was greater (hazard ratio [HR], 5.000; 95% CI, 0.938–26.665; \( p = 0.060 \)) than for those receiving both treatments. However, the number of patients was too small to obtain reliable results.

**NAFLD and survival in HR+/HER2−, nonmetastatic breast cancer**

Interestingly, there were fewer progression events in patients with NAFLD than in non-NAFLD patients (10 vs. 45 events). The median DFS of HR+/HER2− breast cancer patients without NAFLD was 59.3 months (45.6–73.0), whereas in patients who developed NAFLD, the
median DFS was not reached. The HR for NAFLD to relapse or progress was 0.386 (95% CI, 0.19–0.77; \( p = 0.007 \)) (Figure 2).

There was no significant difference in OS based on NAFLD development among breast cancer patients (HR, 0.294; 95% CI, 0.035–2.446; \( p = 0.257 \)) (Figure 2).

Compared to other conventional prognostic factors such as age, tumor size, node involvement, and Ki-67 level, newly developed NAFLD was associated with longer DFS (HR, 0.386; 95% CI, 0.19–0.77; \( p = 0.007 \)). A higher histological grade (grade 3) was associated with shorter DFS (HR, 2.286; 95% CI, 1.199–4.359; \( p = 0.011 \)) (Table 3). Multivariate analysis confirmed that NAFLD (HR, 0.359; 95% CI, 0.180–0.716; \( p = 0.004 \)) and higher histological grade (HR, 2.482; 95% CI, 1.300–4.739; \( p = 0.006 \)) were independent factors for DFS.

Due to the imbalanced number of patients receiving adjuvant hormone therapy alone compared to adjuvant chemotherapy followed by hormone therapy, we performed a sub-analysis by sorting out all patients who received adjuvant hormone therapy alone (7 patients). In the remaining 153 patients who received chemotherapy followed by hormone therapy, the association between NAFLD and progression was consistent (HR, NAFLD for DFS, 0.437; 95% CI, 0.215–0.887; \( p < 0.022 \)). We also filtered out those who progressed earlier than 24 months (45 patients) to eliminate patients who had events before developing NAFLD and found that in the remaining 115 patients, the effect of NAFLD on DFS in HR+HER2– breast cancer was consistent (HR, 0.332; 95% CI, 0.126–0.823; \( p < 0.025 \)).

**Figure 2.** DFS and OS according to the development of NAFLD during treatment. (A) The median DFS was 59.3 months (95% CI, 45.5–73.0) in the non NAFLD group; whereas in the NAFLD group the median DFS was not reached (HR, 0.386; 95% CI, 0.19–0.77; \( p = 0.007 \)). (B) The survival estimation of breast cancer patients who developed NAFLD was not different from that of non-NAFLD patients: mean survival was 108.23 ± 3.525 months vs. 87.79 ± 1.283 months. The median survival estimation of both groups was not reached (HR for OS, 0.294; 95% CI, 0.035–2.446; \( p = 0.257 \)).

DFS = disease-free survival; OS = overall survival; NAFLD = non-alcoholic fatty liver disease; CI = confidence interval; HR = hazard ratio.
DISCUSSION

NAFLD that develops during hormonal treatment in HR+ breast cancer is associated with visceral obesity and metabolic abnormalities. However, in this study, breast cancer patients who developed NAFLD had good prognosis.

NAFLD prevalence has been increasing worldwide [17] and is higher in breast cancer patients, compared to the normal population, depending on the modalities used to diagnose NAFLD [18]. In this study, the prevalence of NAFLD was 35% in patients with breast cancer who received hormonal therapy. Similar results have been reported in previous studies [19].

Visual assessment of NAFLD in this study was performed using USG as part of the routine surveillance for breast cancer progression. Bedside USG is easy to use, noninvasive, and a readily available diagnostic tool but it has some limitations such as being subject to interobserver variability and low sensitivity if steatosis is < 20% [20,21]. However, when fat accumulation in the liver > 20%, bedside USG has 90% sensitivity in diagnosing NAFLD [20]. Liver biopsy, which is the gold standard test but also more invasive, is not routinely performed during surveillance for breast cancer patients for the diagnosis of steatohepatitis and NASH. Thus, the prevalence of NAFLD in this study was higher than that reported in previous studies that used liver biopsy to diagnose NAFLD [22].

Several risk factors are associated with newly developed NAFLD such as age, BMI, anthropometric size, dyslipidemia, MetS, and hormonal treatment for breast cancer [23-25]. In this study, further analysis revealed that being overweight, waist circumference > 80 cm, low LDL-C, and high triglyceride levels were associated with NAFLD. MetS, as a group of metabolic abnormalities, was not included in multivariate analysis which analyzed its

---

Table 3. Survival analysis of variables related to DFS and OS

| Variable                  | DFS Univariate | DFS Multivariate | OS Univariate |
|---------------------------|----------------|------------------|---------------|
|                           | HR (95% CI)*  | p*              | HR (95% CI)*  | p*              |
| Age (yr)                  |                |                  |               |
| ≤ 50                      | 1 (reference)  | -                | 1 (reference) | -                |
| ≥ 50                      | 1.414 (0.831–2.406) | 0.201          | -              | 0.879 (0.196–3.932) | 0.866 |
| Tumor size                |                |                  |               |
| T1–T2                     | 1 (reference)  | -                | 1 (reference) | -                |
| T3–T4                     | 1.589 (0.929–2.777) | 0.091          | -              | 2.768 (0.534–14.271) | 0.224 |
| Node involvement          |                |                  |               |
| N0–N1                     | 1 (reference)  | -                | 1 (reference) | -                |
| N2–N3                     | 1.540 (0.774–3.066) | 0.219          | -              | 1.122 (0.135–9.324) | 0.915 |
| Grade (available in 131 patients) |            |                  |               |
| G1–G2                     | 1 (reference)  | 1 (reference)    | 1 (reference) | -                |
| G3                        | 2.286 (1.199–4.359) | 0.011          | 2.482 (1.300–4.739) | 0.006  |
| Unknown                   | 1.821 (0.839–3.932) | 0.130          | 1.930 (90.888–4.198) | 0.097  |
| Ki-67 (available in 44 patients) |            |                  |               |
| < 20%                     | 1 (reference)  | -                | 1 (reference) | -                |
| ≥ 20%                     | 3.004 (0.750–12.030) | 0.120          | -              | 329,555 (0.000–) | 0.948 |
| Unknown                   | 1.868 (0.666–5.239) | 0.235          | -              | 13,656 (0.00–) | 0.961 |

NAFLD = non-alcoholic fatty liver disease; DFS = disease-free survival; OS = overall survival; HR = hazard ratio; CI = confidence interval; T = tumor; N = node involvement; G = histological grade; Ki-67 = proliferation index.

*Univariate, †multivariate, data are analyzed by binomial Cox proportional hazard model; p < 0.05 is considered as statistically significant (bold-faced).
metabolic components. Waist circumference directly indicates visceral obesity, whereas metabolic syndrome, dyslipidemia, and being overweight are closely associated with the same.

The median time for developing NAFLD is 1–3 years after the initiation of hormonal treatment [26], similar to our results. SERM or Tam contribute to newly developed NAFLD, similar to the effect of aromatase inhibitors [23,24]. The mechanisms by which SERM induces NAFLD have been described previously. Tam has been shown to increase hepatic fat accumulation by blocking estrogen, which disrupts hepatic lipid homeostasis, increases triglycerides, and lowers LDL-C [27]. Patients with breast cancer receiving Tam have higher triglyceride levels and lower LDL-C and cholesterol levels [27]. Aromatase inhibitors may also induce NAFLD; however, the underlying mechanisms are not known. Although several studies have revealed that Tam has a greater effect in promoting newly developed NASH than AI [13], the difference was not significant with our data. The use of only Tam increased the risk of NAFLD compared to Tam + AI but again the difference was not significant.

The effect of NAFLD on prognosis of breast cancer remains a concern. Previous studies have shown that NAFLD worsens the prognosis of breast cancer patients independent of stage, lymph node involvement, diabetes, and obesity [23,24]. In contrast, our findings showed that NAFLD improved the survival of early breast cancer patients, similar to the results of Zheng et al. [28].

Low levels of insulin-like growth factor-1 (IGF-1) in NAFLD [29] may contribute to longer DFS in breast cancer patients with NAFLD. The synthesis of IGF-1 is downregulated in NAFLD, and the level of IGF-1 is associated with the severity of NAFLD [29]. In the liver, IGF-1 decreases lipogenesis, triglyceride accumulation, and reactive oxygen species, improves insulin resistance and mitochondrial function, induces senescence of hepatic stellate cells (HSC), and inhibits the activation of HSCs and fibrosis, thereby protecting against steatohepatitis and NASH [30]. IGF-1 signaling through the IGF-1 receptor is functional in any type of breast cancer. IGF-1 promotes proliferation and is anti-apoptotic. Hence, it contributes to antiestrogen resistance, and low IGF-1 levels in NAFLD may improve antiestrogen action.

This study has several limitations. First, it was a retrospective study, which may have made selection bias inevitable. Second, using USG to diagnose NAFLD makes it impossible to determine severity of steatosis and degree of fibrosis which may influence the prognosis. The relatively small sample size, and less aggressive phenotypes compared to the entire HR+ breast cancer cohort due to incomplete retrospective variables and shorter follow-up made selection bias unavoidable, which may be a major limitation.

The study findings suggest that women with breast cancer who received hormonal therapy, who were overweight, had waist circumference ≥ 80 cm, had high triglyceride levels, and had low LDL-C levels had an increased risk of developing NAFLD. Developing NAFLD during hormonal treatment does not compromise survival. DFS of women who develop NAFLD during hormone treatment was longer compared to those who do not develop NAFLD. These results may have practical implications when treating such patients. Due to the complexity of possible mechanisms involved in the interplay between estrogen, lipid metabolism and growth factor signaling, it is important for clinicians who treat breast cancer patients with hormone therapy to continue hormone therapy, even when NAFLD is documented during treatment evaluation.
ACKNOWLEDGMENTS

The authors would like to thank Kurnianda J, Purwanto I, Hutajulu SH (Division of Hematology and Medical Oncology, Department of Internal Medicine, Faculty of Medicine, UGM, Indonesia) for endless support and thoughtful discussion, and Pudyasari RS and Ariesta NF, for managing patient data. We also express gratitude to the Cancer Registry, Faculty of Medicine, Public Health and Nursing UGM, and Dr. Sardjito Hospital for facilitating data collection.

SUPPLEMENTARY MATERIALS

Supplementary Table 1
Comparison of the whole cohort and eligible sample of HR+/HER2– breast cancer

Click here to view

REFERENCES

1. Chalasani N, Younossi Z, Lavine JE, Diehl AM, Brunt EM, Cusi K, et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 2012;142:1592-609.
   PUBMED | CROSSREF
2. Lomonaco R, Sunny NE, Bril F, Cusi K. Nonalcoholic fatty liver disease: current issues and novel treatment approaches. Drugs 2013;73:1-144.
   PUBMED | CROSSREF
3. Arguello G, Balboa E, Arrese M, Zanlungo S. Recent insights on the role of cholesterol in non-alcoholic fatty liver disease. Biochim Biophys Acta 2015;1852:1765-78.
   PUBMED | CROSSREF
4. Moon SW, Kim SY, Jung JY, Kang YA, Park MS, Kim YS, et al. Relationship between obstructive lung disease and non-alcoholic fatty liver disease in the Korean population: Korea National Health and Nutrition Examination Survey, 2007-2010. Int J Chron Obstruct Pulmon Dis 2018;13:2603-41.
   PUBMED | CROSSREF
5. Marcuccilli M, Chonchol M. NAFLD and chronic kidney disease. Int J Mol Sci 2016;17:562.
   PUBMED | CROSSREF
6. Kim GA, Lee HC, Choe J, Kim MJ, Lee MI, Chang HS, et al. Association between non-alcoholic fatty liver disease and cancer incidence rate. J Hepatol 2017;68:140-6.
   PUBMED | CROSSREF
7. Kwak MS, Yim JY, Yi A, Chung GE, Yang JI, Kim D, et al. Nonalcoholic fatty liver disease is associated with breast cancer in nonobese women. Dig Liver Dis 2019;51:1030-5.
   PUBMED | CROSSREF
8. Saphner T, Triest-Robertson S, Li H, Holzman P. The association of nonalcoholic steatohepatitis and tamoxifen in patients with breast cancer. Cancer 2009;115:3189-95.
   PUBMED | CROSSREF
9. Lee S, Jung Y, Bae Y, Yun SP, Kim S, Jo H, et al. Prevalence and risk factors of nonalcoholic fatty liver disease in breast cancer patients. Tumori 2017;103:187-92.
   PUBMED | CROSSREF
10. Nseir W, Abu-Rahmeh Z, Tsipis A, Mograbi J, Mahamid M. Relationship between non-alcoholic fatty liver disease and breast cancer. Isr Med Assoc J 2017;19:242-5.
   PUBMED
11. Ahmed MH, Osman KA. Tamoxifen induced non-alcoholic steatohepatitis (NASH): has the time come for the oncologist to be diabetologist [letter]. Breast Cancer Res Treat 2006;97:223-4.
   PUBMED | CROSSREF
12. Yang YJ, Kim KM, An JH, Lee DB, Shim JH, Lim YS, et al. Clinical significance of fatty liver disease induced by tamoxifen and toremifene in breast cancer patients. Breast 2016;28:677-2.
   PUBMED | CROSSREF
13. Hong N, Yoon HG, Seo DH, Park S, Kim SI, Sohn JH, et al. Different patterns in the risk of newly developed fatty liver and lipid changes with tamoxifen versus aromatase inhibitors in postmenopausal women with early breast cancer: A propensity score-matched cohort study. Eur J Cancer 2017;82:103-14. 
PUBMED | CROSSREF

14. Moy FM, Bulgiba A. The modified NCEP ATP III criteria maybe better than the IDF criteria in diagnosing Metabolic Syndrome among Malays in Kuala Lumpur. BMC Public Health 2010;10:e678. 
PUBMED | CROSSREF

15. Tan CE, Ma S, Wai D, Chew SK, Tai ES. Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians? Diabetes Care 2004;27:1182-6. 
PUBMED | CROSSREF

16. Hamer OW, Aguirre DA, Casola G, Lavine JE, Woenckhaus M, Sirlin CB. Fatty liver: imaging patterns and pitfalls. Radiographics 2006;26:1637-53. 
PUBMED | CROSSREF

17. Loomba R, Sanyal AJ. The global NAFLD epidemic. Nat Rev Gastroenterol Hepatol 2013;10:686-90. 
PUBMED | CROSSREF

18. Lee YS, Lee HS, Chang SW, Lee CU, Kim JS, Jung YK, et al. Underlying nonalcoholic fatty liver disease is a significant factor for breast cancer recurrence after curative surgery. Medicine (Baltimore) 2019;98:e17277. 
PUBMED | CROSSREF

19. Lee B, Jung EA, Yoo JI, Kim SG, Lee CB, Kim YS, et al. Prevalence, incidence and risk factors of tamoxifen-related non-alcoholic fatty liver disease: a systematic review and meta-analysis. Liver Int 2020;40:1344-55. 
PUBMED | CROSSREF

20. Khov N, Sharma A, Riley TR. Bedside ultrasound in the diagnosis of nonalcoholic fatty liver disease. World J Gastroenterol 2014;20:6821-5. 
PUBMED | CROSSREF

21. Cengiz M, Sentürk S, Cetin B, Bayrak AH, Bilek SU. Sonographic assessment of fatty liver: intraobserver and interobserver variability. Int J Clin Exp Med 2014;7:5453-60. 
PUBMED

22. Williams CD, Stengel J, Asike MI, Torres DM, Shaw J, Contreras M, et al. Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study. Gastroenterology 2011;140:124-31. 
PUBMED | CROSSREF

23. Yan M, Wang J, Xuan Q, Dong T, He J, Zhang Q. The relationship between tamoxifen-associated nonalcoholic fatty liver disease and the prognosis of patients with early-stage breast cancer. Clin Breast Cancer 2017;17:195-203. 
PUBMED | CROSSREF

24. Lee JJ, Yu JH, Ahn SG, Lee HW, Jeong J, Lee KS. Aromatase inhibitors and newly developed nonalcoholic fatty liver disease in postmenopausal patients with early breast cancer: a propensity score-matched cohort study. Oncologist 2019;24:e653-61. 
PUBMED | CROSSREF

25. Chang HT, Pan HJ, Lee CH. Prevent tamoxifen-related nonalcoholic fatty liver disease in breast cancer patients. Clin Breast Cancer 2018;18:e677-85. 
PUBMED | CROSSREF

26. National Institute of Diabetes and Digestive and Kidney Diseases. LiverTox: Clinical and Research Information on Drug-induced Liver Injury [Internet]. Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Disease; 2012. 
PUBMED | CROSSREF

27. Tominaga T, Kimijima I, Kimura M, Takatsuka Y, Takashima S, Nomura Y, et al. Effects of toremifene and tamoxifen on lipid profiles in post-menopausal patients with early breast cancer: interim results from a Japanese phase III trial. Jpn J Clin Oncol 2010;40:627-33. 
PUBMED | CROSSREF

28. Zheng Q, Xu F, Nie M, Xia W, Qin T, Qin G, et al. Selective estrogen receptor modulator-associated nonalcoholic fatty liver disease improved survival in patients with breast cancer. Medicine (Baltimore) 2015;94:e178. 
PUBMED | CROSSREF

29. Takahashi Y. The role of growth hormone and insulin-like growth factor-I in the liver. Int J Mol Sci 2017;18:E1447. 
PUBMED | CROSSREF

30. Nishizawa H, Iguchi G, Fukuoka H, Takahashi M, Suda K, Bando H, et al. IGF-I induces senescence of hepatic stellate cells and limits fibrosis in a p53-dependent manner. Sci Rep 2016;6:34605. 
PUBMED | CROSSREF